AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease

Shin-Etsu Chemical to invest in pharmaceutical cellulose business

L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

Innovaoleo launches Omega 3 Star for food, nutraceutical and pet nutrition

Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health

Lupin bags EcoVadis Silver Medal for sustainability excellence

Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring

Clariant unveils natural preservation blend for cosmetics 'Nipaguard SCE Vita'

Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations

Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset

This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million

Bionova opens Fremont process development and pilot plant